Clinical Trial Update: VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naïve Participants With Genotype 1 Chronic Hepatitis C Virus Infection [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing twice-daily versus every-8-hours dosing of telaprevir in treatment-naive genotype 1 chronic hepatitis C, with results posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Telaprevir (telaprevir)

Snippet

Sponsor: Janssen Infectious Diseases BVBA | Conditions: Genotype 1 Chronic Hepatitis C, Treatment Naive | Phase 3 | Status: COMPLETED | Results posted: 2014-06-04